23andMe Therapeutics

Discovering novel treatments for patients with serious unmet medical needs.

Our genetic research gives everyday people the opportunity to make a difference by participating in a new kind of research—online, from anywhere.

The 23andMe cohort is the largest re-contactable research database of genotypic and phenotypic information in the world. At 23andMe, we believe our research platform can help discover novel treatments for patients with serious unmet medical needs.

23andMe’s Therapeutics division focuses on research and drug development.

The team is committed to discovering and developing novel therapies to improve patient lives through the study of human genetics. We currently have research programs across several therapeutic areas, including but not limited to oncology, respiratory, and cardiovascular diseases.
In July 2018, 23andMe and GlaxoSmithKline (GSK) signed an exclusive agreement to leverage genetic insights for the development of novel medicines. This multi-year collaboration is expected to identify novel drug targets, tackle new subsets of disease and enable rapid progression of clinical programs.

Our Beliefs

Focus on helping patients

Innovative and rigorous science

Integrity, honesty and transparency

Helping people reach their full potential

Effective decision making